Retrospective Cohort Study
Copyright ©The Author(s) 2021.
World J Gastroenterol. Apr 21, 2021; 27(15): 1630-1642
Published online Apr 21, 2021. doi: 10.3748/wjg.v27.i15.1630
Table 3 Characteristics of all patients (n = 172)
With RAP (n = 29)Without RAP (n = 143)Risk difference [95%CI] P value
n (%)
n (%)
Median age 61 (IQR 18) 65 (IQR 15) NA 0.65
Sex (M)13 (44.8) 58 (40.6) NA 0.67
Location of cyst
Head 16 (55.2) 65 (45.5) 0.10 [-0.10, 0.30] 0.34
Neck 2 (6.9) 7 (4.9) 0.02 [-0.08, 0.12] 0.69
Body 8 (27.6) 32 (22.4) 0.05 [-0.12, 0.23] 0.56
Tail 3 (10.3) 37 (25.9) -0.16 [-0.29, -0.02] 0.02
Diffuse 0 (0) 2 (1.4) -0.01 [-0.06, 0.04] 0.59
Main pancreas duct > 10 4 (13.8) 10 (7.0) 0.07 [-0.06, 0.20] 0.31
Cyst size > 3 6 (20.7) 36 (25.2) -0.04 [-0.21, 0.12] 0.59
Solid component 7 (24.1) 46 (32.2) -0.08 [-0.25, 0.09] 0.36
Malignancy 6 (20.7) 24 (16.8) 0.04 [-0.12, 0.20] 0.63
Pathological subtype
Intestinal 10 (34.5)11 (7.7) 0.27 [0.09, 0.45] 0.003
Gastric 3 (10.3) 43 (30.1) -0.20 [-0.33, -0.06] 0.004
Pancreatobiliary 7 (24.1) 15 (10.5) 0.14 [-0.03, 0.30] 0.10
Oncocytic 0 (0) 3 (2.1) -0.02 [-0.07, 0.03] 0.43
Unknown 9 (31.0) 71 (49.7) -0.19 [-0.37, 0.001] 0.05
Cyst type
IPMN total 23 (79.3) 78 (54.5) 0.25 [0.08, 0.41] 0.004
BD-IPMN 15 (51.7) 44 (30.8) 0.21 [0.01, 0.41] 0.04
MD-IPMN8 (27.6) 34 (23.8) 0.04 [-0.14, 0.22] 0.67
Non-IPMN 6 (20.7) 65 (45.5) -0.25 [-0.42, -0.08] 0.004